HC Wainwright Cuts Earnings Estimates for Nuvectis Pharma

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Analysts at HC Wainwright lowered their FY2026 EPS estimates for shares of Nuvectis Pharma in a report released on Wednesday, November 4th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($1.91) per share for the year, down from their previous estimate of ($1.02). HC Wainwright currently has a “Buy” rating and a $39.00 target price on the stock. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Nuvectis Pharma’s Q4 2026 earnings at ($0.27) EPS, FY2027 earnings at ($1.97) EPS and FY2028 earnings at ($2.35) EPS.

Several other research firms have also issued reports on NVCT. Loop Capital set a $40.00 price objective on Nuvectis Pharma in a research note on Tuesday, September 1st. Cantor Fitzgerald initiated coverage on Nuvectis Pharma in a research report on Monday, August 24th. They set an “overweight” rating on the stock. Weiss Ratings upgraded Nuvectis Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, September 21st. Finally, Lucid Cap Mkts upgraded Nuvectis Pharma to a “strong-buy” rating in a research report on Tuesday, September 1st. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Nuvectis Pharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.25.

Nuvectis Pharma Price Performance

Shares of NASDAQ NVCT opened at $17.76 on Friday. Nuvectis Pharma has a 1-year low of $5.55 and a 1-year high of $29.27. The business’s 50 day moving average is $20.98 and its two-hundred day moving average is $14.81. The stock has a market capitalization of $579.76 million, a P/E ratio of -9.40 and a beta of -0.21.

Nuvectis Pharma (NASDAQ:NVCT) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.78).

Hedge Funds Weigh In On Nuvectis Pharma

Several hedge funds have recently added to or reduced their stakes in NVCT. Legal & General Group Plc purchased a new stake in Nuvectis Pharma in the 2nd quarter worth about $31,000. Bank of America Corp DE bought a new stake in Nuvectis Pharma in the second quarter worth about $218,000. Avalon Trust Co bought a new stake in Nuvectis Pharma in the second quarter worth about $257,000. Deutsche Bank AG purchased a new position in shares of Nuvectis Pharma during the second quarter valued at approximately $310,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Nuvectis Pharma during the second quarter valued at approximately $676,000. 96.77% of the stock is currently owned by institutional investors.

About Nuvectis Pharma

Nuvectis Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, with an emphasis on cancers that have limited therapeutic options. The company is headquartered in Fort Lee, New Jersey, and its common stock trades on the Nasdaq Capital Market under the symbol NVCT.

Nuvectis Pharma’s lead product candidate is NXP800, an orally administered small-molecule inhibitor of heat shock protein 90 (HSP90). The company is evaluating NXP800 in clinical studies for certain advanced solid tumors, including platinum-resistant ovarian cancer and cholangiocarcinoma.